Form 4: Veradigm CPTO Granted 423,998 Restricted Stock Units

Veradigm Inc.'s Chief Product and Technology Officer, Tehsin M. Syed, received a grant of 423,998 Restricted Stock Units under the company's 2024 Stock Incentive Plan.

Summary

• Tehsin M. Syed, Veradigm Inc.'s Chief Product and Technology Officer (CPTO), was granted 423,998 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this award was November 3, 2025.
• The RSUs were granted under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.
• No monetary consideration was paid by the executive for these RSUs at the time of grant, consistent with the nature of such awards.
• The grant vests 25% on each of the first four anniversaries of the Grant Date (November 3, 2025).

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to a key executive is a standard practice for aligning management incentives with long-term shareholder value. While routine, it indicates a commitment to retaining leadership and linking their compensation to company performance.

Positives

• The grant of Restricted Stock Units aligns the executive's long-term interests with those of shareholders, incentivizing performance and retention.
• This award is part of a standard compensation structure designed to attract and retain key talent.

Negatives

• The issuance of new shares upon vesting could lead to a minor dilutive effect on existing shareholders, though this is typical for equity compensation plans.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction. General risks associated with equity compensation, such as potential for misalignment if performance targets are not met, are inherent but not explicitly stated here.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted RSUs.

Industry Context

The grant of Restricted Stock Units to a key executive like the Chief Product and Technology Officer is a common practice across the technology and healthcare IT sectors. It serves as a critical tool for talent retention and performance alignment, reflecting standard industry compensation strategies for senior leadership.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice among publicly traded companies, particularly in the technology and healthcare IT industries, similar to companies like Cerner (now Oracle Health) or Epic Systems (though private).
• The four-year vesting schedule with annual increments is a common structure designed to promote long-term commitment and align executive incentives with sustained shareholder value creation, consistent with benchmarks observed at peer companies such as Athenahealth or Allscripts (Veradigm's former parent).
• The grant size of 423,998 RSUs for a CPTO role would typically be evaluated against the company's market capitalization, the executive's total compensation package, and peer group benchmarks to assess its competitiveness and appropriateness.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting, but also improved alignment of executive interests with long-term shareholder value.
• Employees: Signals the company's strategy for executive retention and competitive compensation, which can positively influence overall employee morale and talent attraction.

Next Steps

• The RSUs will vest 25% annually on the first four anniversaries of the November 3, 2025 grant date.

Key Dates

Keywords

Veradigm Inc., MDRX, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4, Tehsin M. Syed, CPTO, Stock Incentive Plan